Cisapride(R 51619) is a nonselective 5-HT4 receptor agonist, it is also a potent human ether-à-go-go-related gene (hERG) potassium channel inhibitor.
IC50 Value: 0.14 μM(EC50 for 5-HT4 receptor) [1]; 9.8 μM (Kv4.3)
Target: 5-HT4 Receptor
in vitro: Cisapride showed higher inhibitory effects on a hERG current, as indicated by its IC50 of 9.4 × 10-9 M. cisapride on cloned Kv4.3 channels stably expressed in Chinese hamster ovary cells were investigated using the whole-cell patch-clamp technique. Cisapride inhibited Kv4.3 in a concentration-dependent manner with IC50 values of 9.8 uM .
in vivo: Cisapride (1 mg/kg i.v.), when administered 10 min after the start of GR113808 infusion, did not stimulate either antral or colonic motor activity under treatment with GR113808. The enhanced antral or colonic motor activity induced by these drugs was antagonized by treatment with GR113808 in dogs . cisapride could not bring about more colitis damages through 5HT(4) receptors. Based on the present study further researches are required for investigating the exact roles of 5HT(4) receptors in the pathogenesis of ulcerative colitis.
Toxicity: cardiac arrythmies

5-HT Receptor
Clozapine N-oxide
CP-809101
Cyclobenzaprine hydrochloride
Dapoxetine Hydrochloride
Desvenlafaxine
Dihydroergotamine mesylate
Doxepin
Duloxetine
Eletriptan
Eltoprazine
Escitalopram
Fluoxetine
Fluvoxamine
Granisetron
IIoperidone
Lasmiditan
Lorcaserin
Loxapine